DENTSPLY SIRONA (XRAY) Cut to Hold at Credit Suisse Group

DENTSPLY SIRONA (NASDAQ:XRAY) was downgraded by investment analysts at Credit Suisse Group to a “hold” rating in a report issued on Friday. They currently have a $73.00 price objective on the medical instruments supplier’s stock. Credit Suisse Group’s price objective would indicate a potential upside of 7.61% from the stock’s current price.

XRAY has been the subject of a number of other research reports. Deutsche Bank started coverage on DENTSPLY SIRONA in a research report on Friday, December 8th. They issued a “buy” rating and a $81.00 price objective for the company. Zacks Investment Research upgraded DENTSPLY SIRONA from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. BidaskClub downgraded DENTSPLY SIRONA from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 2nd. Cleveland Research downgraded DENTSPLY SIRONA from a “buy” rating to a “neutral” rating in a research report on Thursday, October 5th. Finally, Barrington Research upgraded DENTSPLY SIRONA from a “market perform” rating to an “outperform” rating and set a $73.00 price objective for the company in a research report on Monday, November 6th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the stock. DENTSPLY SIRONA has a consensus rating of “Hold” and a consensus target price of $69.15.

Shares of DENTSPLY SIRONA (NASDAQ:XRAY) opened at $67.84 on Friday. The stock has a market capitalization of $15,581.69, a P/E ratio of 27.03, a price-to-earnings-growth ratio of 2.49 and a beta of 1.31. The company has a quick ratio of 1.59, a current ratio of 2.32 and a debt-to-equity ratio of 0.21. DENTSPLY SIRONA has a fifty-two week low of $52.53 and a fifty-two week high of $68.98.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $978.99 million. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. The company’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.66 EPS. equities research analysts forecast that DENTSPLY SIRONA will post 2.65 earnings per share for the current fiscal year.

In related news, CFO Nicholas W. Alexos bought 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was acquired at an average price of $65.85 per share, for a total transaction of $3,292,500.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Francis J. Lunger sold 8,900 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $65.90, for a total value of $586,510.00. The disclosure for this sale can be found here. 1.99% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in shares of DENTSPLY SIRONA by 2.5% during the 2nd quarter. Vanguard Group Inc. now owns 22,728,062 shares of the medical instruments supplier’s stock worth $1,473,688,000 after buying an additional 562,993 shares during the period. Ruane Cunniff & Goldfarb Inc. lifted its position in shares of DENTSPLY SIRONA by 0.5% during the 3rd quarter. Ruane Cunniff & Goldfarb Inc. now owns 8,890,655 shares of the medical instruments supplier’s stock worth $531,750,000 after buying an additional 40,767 shares during the period. Principal Financial Group Inc. lifted its position in shares of DENTSPLY SIRONA by 6.7% during the 3rd quarter. Principal Financial Group Inc. now owns 6,910,770 shares of the medical instruments supplier’s stock worth $413,333,000 after buying an additional 436,338 shares during the period. Jackson Square Partners LLC lifted its position in shares of DENTSPLY SIRONA by 15.6% during the 3rd quarter. Jackson Square Partners LLC now owns 6,334,906 shares of the medical instruments supplier’s stock worth $378,890,000 after buying an additional 855,199 shares during the period. Finally, Neuberger Berman Group LLC lifted its position in shares of DENTSPLY SIRONA by 5.3% during the 3rd quarter. Neuberger Berman Group LLC now owns 5,781,470 shares of the medical instruments supplier’s stock worth $345,790,000 after buying an additional 292,505 shares during the period. Institutional investors and hedge funds own 96.14% of the company’s stock.

TRADEMARK VIOLATION WARNING: “DENTSPLY SIRONA (XRAY) Cut to Hold at Credit Suisse Group” was first published by American Banking and Market News and is owned by of American Banking and Market News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/07/dentsply-sirona-xray-cut-to-hold-at-credit-suisse-group.html.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.